Improving Hypertension Detection and Control Through a Hypertension Certification Program Based Upon the Hypertension Canada Guidelines (RxPATH)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 890
- 试验地点
- 2
- 主要终点
- The difference in change in systolic blood pressure between Intervention and Control patients.
研究概览
简要总结
This study will assess the impact of a hypertension management certification program for community pharmacists on the blood pressure control of patients managed by the pharmacists enrolled. The investigators will compare the systolic blood pressure of patients identified to have hypertension in the community that are followed by pharmacists who have undergone the certification course, and compare their blood pressure outcomes to subjects managed by pharmacists who have not yet received the training.
详细描述
Hypertension Canada proposes the first "Hypertension Canada Professional Certification Program"(HC-PCP), specifically designed for Alberta pharmacists, to provide care and support to those at risk for or living with hypertension. Through this program, the investigators hope to help with prevention of the costly and chronic conditions to which hypertension often leads, like kidney failure, stroke, and heart disease.
The HC-PCP aims to provide training to pharmacists in the screening, prevention, and management of hypertension. It has been identified that the development and implementation of this certification program provides a unique opportunity to evaluate the impact of such a program on blood pressure reduction.
The investigators are aiming to assess the impact of pharmacist management on blood pressure control in patients with hypertension.
The development of the HC-PCP and the evaluation of its impact will occur in 2 phases. Phase 1 involves the development and implementation of the educational portion of the certification program. Phase 2 involves conducting a 1 year long study to assess the impact of the HC-PCP on blood pressure in patients with poorly controlled hypertension. This will be launched in pharmacies in Alberta.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
By necessity, pharmacists in the intervention groups cannot be blinded. However, pharmacists will not be told about the cluster randomization, just that they will be contacted about when they will receive the HC-PCP. During the control period, pharmacists will be told that their patients will be enrolled in an observational hypertension registry to prepare for the intervention phase.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with poorly controlled blood pressure (>140/90mmHg or >130/80mmHg if they have diabetes).
排除标准
- •Unwilling to sign the consent form.
- •Unwilling to participate in follow up visits.
- •Current hypertension urgency or emergency (SBP > 180mmHg or DBP > 120mmHg).
结局指标
主要结局
The difference in change in systolic blood pressure between Intervention and Control patients.
时间窗: From baseline to 3 month follow-up, and up to one year
To detect a 7 millimeters of mercury (mmHg) or greater difference in systolic blood pressure.
次要结局
- Consultant Satisfaction Questionnaire(6 months following follow up)